Inside Labiotech 28 Aug 2020 Content First: Labiotech’s Vision for 2020 and Beyond 2020 has been a challenging year for all of us. At Labiotech, we’re among the lucky businesses that weren’t affected too much by the pandemic. Our activity is online, and our team is used to working remotely, so fortunately, we were able to operate as normal during the lockdown. Still, a lot has happened in […] August 28, 2020 - 7 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
Expert Advice 26 Aug 2020 Negotiating Early-Stage Biotech Valuation: VC vs Entrepreneur There is usually a big disparity between investors and entrepreneurs regarding the valuation of an early-stage biotech company. How can both sides navigate this negotiation and reach a fair agreement? Many entrepreneurs in biotech might be puzzled when they get a low pre-money valuation for a product with high potential. Even when a product in […] August 26, 2020 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2020 What Does Unity’s Phase II Fail Mean for European Anti-Aging Research? A drug developed by the US firm Unity Biotechnology — designed to slow the aging process — recently proved a dud in phase II for the treatment of osteoarthritis. How is this high-profile setback affecting European biotechs developing anti-aging treatments? Aging is a complex, multi-faceted process that makes people vulnerable to a wide range of […] August 25, 2020 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Expert Advice 24 Aug 2020 Why a US Presence Can Help European Biotechs Get Ahead While there is no doubt that Europe has a thriving biotech scene, it can really help a European company to succeed if it has a US presence. No one knows this better than Patricia Zilliox, CEO of French biotech company Eyevensys, who has lived and worked in the US for many years. Zilliox is French, […] August 24, 2020 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 20 Aug 2020 Is Hepatitis D Healthcare Being Overlooked? Despite the recent EU approval of the first hepatitis D treatment, low public awareness remains an obstacle to tackling this aggressive infection. Earlier this month, the peptide drug Hepcludex became the first drug greenlit for hepatitis D treatment in Europe. This was a conditional market authorization granted to the German company MYR Pharmaceuticals based on […] August 20, 2020 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 19 Aug 2020 7 Biotech Books to Read in the Sun this Summer Here are seven biotech books for the summer that will take you from CRISPR gene editing to the microbiome to pharma and economics, as well as sci-fi that takes biotech to space. The excitement of the summer break has been dampened somewhat by the ever-present threat of the Covid-19 pandemic. No matter where you end […] August 19, 2020 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 Aug 2020 Women’s Health Gains Traction as Bayer Pays €736M for UK Firm Bayer’s recent €736M ($875M) acquisition of KaNDy Therapeutics could herald growing investor interest in women’s health – a historically neglected field in the biotech and pharma industry. Through this deal, Bayer has snapped up KaNDy Therapeutics’ first-in-class drug for treating hot flashes and night sweats, which often occur during the menopause. In a phase IIb […] August 18, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 17 Aug 2020 CureVac Continues Covid-19 Vaccine Funding Frenzy with €180M IPO The share price of CureVac has skyrocketed almost fivefold after the Covid-19 vaccine developer priced a Nasdaq IPO at €180M ($213M). The excitement around messenger RNA (mRNA) vaccines against Covid-19 could also benefit other players in mRNA therapeutics. CureVac’s IPO was priced at €14 ($16) per share, giving the German company a valuation of around […] August 17, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Aug 2020 Record Funding for Gene and Cell Therapy Accompanies Turbulent Times European companies developing advanced therapies such as gene and cell therapies secured at least €2.2B ($2.6B) in the first half of 2020. While this is encouraging in the face of Covid-19, it hasn’t been smooth sailing for all startups in the field, with many struggling to stay afloat during crippling national lockdowns. The funding received […] August 14, 2020 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
News and Trends 13 Aug 2020 Why are Some European Biotechs Going Public Without an IPO? European biotech companies are flocking to the Nasdaq Stock Market in 2020, but not all are going the traditional Initial Public Offering (IPO) route. What does this mean for the dominance of the biotech IPO in Europe? In spite of the Covid-19 pandemic, biotech IPOs have continued unabated. In fact, a report from Bioworld found […] August 13, 2020 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 12 Aug 2020 Life at its Limits: The Biotech Industry Embraces Extremophiles Sometimes in biotech, when your standard E. coli just won’t cut it, something more exotic is needed. Could extremophiles be the answer? Given enough time, and the right mutations, life can adapt to thrive in even the most inhospitable environments. From volcanic hot springs to hyper-saline soils, microbes have made their homes pretty much everywhere. […] August 12, 2020 - 7 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 11 Aug 2020 How European Startups Have Advanced Cancer T-Cell Therapy in 2020 With the help of a huge €66M Series A round last week, the German startup T-knife is developing cancer T-cell immunotherapies with the help of genetically modified mice. However, this is just one of several cancer T-cell therapy startups making advances this year, with other innovations including off-the-shelf treatments and a potential universal cancer therapy. […] August 11, 2020 - 8 minutesmins - By Kostas Vavitsas Share WhatsApp Twitter Linkedin Email